EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Targeting GPX4 to Overcome Sorafenib Resistance of Human Hepatocellular Carcinoma by Inducing Ferroptosis

Han‐Hsuan Tang, Chi‐Pei Hsu, Pin‐Yu Su, Shu‐Ping Tsai, Ly Hien Doan, Ching‐Ying Chen, Hsin‐Chih Chen, Pao‐Yuan Wang, Tai‐Shan Cheng, Chi‐Ying F. Huang, Chun‐Li Su

Journal of Cellular Physiology · 2025-08 · 240 (8)

DOI: 10.1002/jcp.70078 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. Sorafenib, a multikinase inhibitor, has been approved as a first‐line systemic therapeutic for HCC patients based on the results of two large clinical trials, in which sorafenib significantly increased life expectancy of patients with Child Pugh A advanced stage of liver cancer, no matter which races they were or whether being infected with hepatitis B or C virus; however, its efficacy is compromised by the resistance of the tumor cells. By using integrative bioinformatics analysis, we identified ferroptosis as a candidate to modulate sorafenib‐resistant HCC. Ferroptosis is a novel, iron‐dependent, non‐apoptotic regulated cell death with characteristics of impaired lipid peroxide repair, redox active iron, and the oxidation of polyunsaturated fatty acids. Here, glutathione peroxidase 4 (GPX4) was further identified as a favorable prognostic factor in cancer survival by analyzing data repositories. Compared to the parental human HCC Huh7 cells, lower expression of GPX4, dysregulated iron homeostasis, and higher expression of acyl‐CoA synthetase long‐chain family member 4 were observed in sorafenib‐resistant Huh7R cells, and the Huh7R cells exhibited higher sensitivity to ferroptosis induction exerted by RSL3, a GPX4 inhibitor. The RSL3‐induced ferroptosis was attenuated by lysosomal blocker bafilomycin A1, indicating that lysosomal degradation of ferritin may confer sensitivity to GPX4‐inactivation‐induced ferroptosis by providing accessible iron. Taken together, our findings demonstrate that GPX4‐inactivation‐induced ferroptosis is a promising and effective treatment option capable of overcoming sorafenib resistance in liver cancer, and our novel gene expression‐screening platform via integrated analysis of differentially expressed genes and pathways allows efficient identification of therapeutic strategies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →